Please login to the form below
hepatocellular carcinoma
This page shows the latest hepatocellular carcinoma news and features for those working in and with pharma, biotech and healthcare.
Roche reports positive phase 3 data for Tecentriq combination in liver cancer
Roche has announced positive new data from a phase 3 study of its Tecentriq (atezolizumab) combination in certain patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
Latest news
-
AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer
In addition to its indications in lung cancer, Imfinzi also holds approvals in locally advanced or metastatic biliary tract cancer, unresectable hepatocellular carcinoma and previously treated advanced bladder cancer.
-
European Commission grants AstraZeneca three new approvals
The Imfinzi/ Imjudo approvals authorise the combination to be used for the first line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC), with the addition of platinum-based
-
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
endpoint of recurrence-free survival (RFS) in patients with early-stage hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
-
Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma
Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).
-
AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer
treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
More from news
Approximately 8 fully matching, plus 66 partially matching documents found.
Latest Intelligence
-
Making Europe a leader in bioscience: boosting trust and opening minds
This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver).
-
Chinese biotech’s global ambitions
Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal squamous cell carcinoma. ... It’s also in phase II trials in patients with previously treated
-
Deal Watch March 2016
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
-
Medius Deal Watch table for April 2015
120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.
-
Pharma deals in April 2015
deacetylase (HDAC) inhibitor in all oncological indications, in particular hepatocellular carcinoma in Asia Pacific (excluding Japan).
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the launch of Nexavar (sorafenib) for the treatment of renal cell
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? ... Accessed March 5, 2019. US Food and Drug Administration. Drugs. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
